Incyte Corporation
Experimental Station Route 141
Henry Clay Road Building E 336
Wilmington,
DE 19880
Phone: 302-498-6700
Fax: 650-855-0572
Web Site: http://www.incyte.com
| Incyte Corporation is a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. The company's CCR2 program is being developed under collaboration with Pfizer, Inc. for inflammatory diseases. Its pipeline also includes sheddase inhibitor (INCB7839), which is in phase IIa clinical trials for solid tumors; CCR5 antagonists for HIV, including INCB9471 in phase IIa and INCB15050 in phase I clinical trials; and 11ßHSD1 inhibitor (INCB13739), which is in phase IIa clinical trial for type 2 diabetes. The company also has preclinical programs under development, such as JAK 2 Program for inflammatory diseases, myeloproliferative disorders, and cancer. Incyte offers its products in the United States, Canada, Germany, Sweden, and the United Kingdom. The company was founded in 1991 and is headquartered in Wilmington, Delaware. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Paul A. Friedman M.D., 65
Chief Exec. Officer, Pres, Director, Member of Non-Management Stock Option Committee and Member of Fin. Committee
|
N/A
|
N/A |
Mr. Roy A. Whitfield , 54
Co-Founder, Director and Member of Audit Committee
|
$
28.00K |
N/A |
Mr. David C. Hastings , 46
Chief Financial Officer and Exec. VP
|
N/A
|
N/A |
Dr. Brian W. Metcalf Ph.D., 62
Chief Drug Discovery Scientist and Exec. VP
|
N/A
|
N/A |
Dr. John Keller Ph.D., 43
Chief Bus. Officer, Exec. VP and Gen. Mang. of the Information Products Group
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
0.32 (3.21%) 
Profile
